




# THE NOVELTY STUDY

Identifying new dimensions in respiratory disease

NOVELTYstudy.com

A large, global, prospective, longitudinal, observational study characterising patients with obstructive lung disease<sup>1</sup>



## Eligibility:

Proportion of adult asthma/COPD patients eligible for:




**Randomised Clinical Trials 5%**<sup>3,4</sup>




**NOVELTY ≥95%**  
All patients aged ≥12 years (in most countries, aged ≥18 years), not participating in an interventional trial

Global (~12,000 patients across 19 countries):



Diverse population: mixed phenotypes and endotypes



## Study Design


Baseline and annual assessments in the clinic, plus 3-monthly assessments captured remotely

2-year extension study at selected sites




## Clinical Assessment

To characterise patients by their clinical profile (phenotype)



## Biomarker Assessment

To characterise patients by disease mechanism (endotype)



A phenotype may be comprised of several endotypes

## The NOVELTY Study

A platform to support the development of personalised healthcare to deliver the right treatment to the right patient at the right time

### References

1. Reddel HK et al. ERJ Open Res 2019;5:00036–2018
2. Bateman ED et al. Lancet Respir Med 2015;3:719-728
3. Travers J et al. Respir Med 2007;101:1313-1320
4. Travers J et al. Thorax 2007;62:219-223